Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017

Open access
Harada-Shiba, Mariko, Arai, Hidenori, Ishigaki, Yasushi, Ishibashi, Shun, Okamura, Tomonori, Ogura, Masatsune, Dobashi, Kazushige, Nohara, Atsushi, Bujo, Hideaki, Miyauchi, Katsumi, Yamashita, Shizuya, Yokote, Koutaro, Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia · 2018 · Journal of Atherosclerosis and Thrombosis

Abstract

Statement1. Familial hypercholesterolemia (FH) is an autosomal hereditary disease with the 3 major clinical features of hyper-LDL-cholesterolemia, premature coronary artery disease and tendon and skin xanthomas. As there is a considerably high risk of coronary artery disease (CAD), in addition to early diagnosis and intensive treatment, family screening (cascade screening) is required (Recommendation level A) 2. For a diagnosis of FH, at least 2 of the following criteria should be satisfied:① LDL-C ≥180 mg/dL, ② Tendon/skin xanthomas, ③ History of FH or premature CAD within 2nd degree blood relatives (Recommendation level A) 3. Intensive lipid-lowering therapy is necessary for the treatment of FH. First-line drug should be statins. (Recommendation level A, Evidence level 3) 4. Screening for CAD as well as asymptomatic atherosclerosis should be conducted periodically in FH patients. (Recommendation level A) 5. For homozygous FH, consider LDL apheresis and treatment with PCSK9 inhibitors or MTP inhibitors. (Recommendation level A) 6. For severe forms of heterozygous FH who have resistant to drug therapy, consider PCSK9 inhibitors and LDL apheresis. (Recommendation level A) 7. Refer FH homozygotes as well as heterozygotes who are resistant to drug therapy, who are children or are pregnant or have the desire to bear children to a specialist. (Recommendation level A).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5551/jat.cr003

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 221

Metadata

Authors
Harada-Shiba, M., Arai, H., Ishigaki, Y., Ishibashi, S., Okamura, T., Ogura, M., Dobashi, K., Nohara, A., Bujo, H., Miyauchi, K., Yamashita, S., Yokote, K., & Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia
Venue
Journal of Atherosclerosis and Thrombosis
Published
2018-08-01
Volume
25
Issue
8
Pages
751-770
ISSN
  • 1340-3478 (ISSN-L)
  • 1880-3873
OpenAlex
W2806550342
Cited by
221
References
10
FWCI
22.15
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. https://app.cochat.ai/papers/10.5551/jat.cr003
The paper
Harada-Shiba, M., Arai, H., Ishigaki, Y., Ishibashi, S., Okamura, T., Ogura, M., Dobashi, K., Nohara, A., Bujo, H., Miyauchi, K., Yamashita, S., Yokote, K., & Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia. (2018). Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.cr003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.